CalciMedica, Inc. CALC
1.37 USD -0.14 (-9.57%)
At closeNov 10, 2026, 4:00 PM EST
1.50 +0.13 +9.49%
After hours · Nov 10, 4:00 PM ET
1.37 Day range 1.52
1.00 52-week range 36.00
- YTD
- -95.84%
- 1 year
- -91.05%
News
benzinga.com CalciMedica Q3 EPS $(0.24) Beats $(1.27) Estimate CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(1.27) by 81.1 percent. This is a 90.73 percent increase over losses of $(2.59)…
globenewswire.com CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates Auxora Phase 1b proof-of-concept data in pulmonary hypertension (PH) and CM5480 IND submission both anticipated in mid-2027
globenewswire.com CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference LA JOLLA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
benzinga.com Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket Inovio shares surged 230% premarket after FDA accelerated Voceryq approval; ClearOne and 22nd Century gained, while RedCloud fell 33.5%.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
benzinga.com CalciMedica Announces Stephen Bardin To Resign As CFO Effective After Q3 2026 10-Q Filing On October 15, 2026, Stephen Bardin, the Chief Financial Officer, principal accounting officer and principal financial officer of CalciMedica, Inc. (the "Company"), provided notice of his…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock rose 34.9% to $2.94 during Thursday's after-market session. The market value of their outstanding shares is at $7.6 million. Senti Biosciences…
defenseworld.net CalciMedica Inc. (NASDAQ:CALC) Stock Has Average Price Target of $50.00 According to Analysts Shares of CalciMedica Inc. (NASDAQ: CALC - Get Free Report) have been assigned a consensus rating of "Hold" from the five brokerages that are covering the stock, MarketBeat reports. One analyst has…
benzinga.com CalciMedica Files Prospectus Supplement For Up To $25M At-The-Market Common Stock Offering https://www.sec.gov/Archives/edgar/data/1534133/000119312526409041/d145394d424b5.htm
globenewswire.com CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium…
benzinga.com CalciMedica Announces 1-For-5 Reverse Stock Split, Effective August 28 CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for
globenewswire.com CalciMedica Announces One-for-Five Reverse Stock Split LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium…- benzinga.com Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9 Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.
benzinga.com CalciMedica Q2 EPS $(0.45) Misses $(0.28) Estimate CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.28) by 60.71 percent. This is a 12.5 percent decrease over losses of…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
benzinga.com Following Type C FDA Meeting, Calcimedica Has Aligned On Phase 2b Trial Endpoints And Patient Population Enrichment Strategy For Its Planned Registration Program Evaluating Auxora In Acute Pancreatitis CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibition therapies for…
prnewswire.com CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints FDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpoints FDA aligned on a…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 million. CalciMedica (NASDAQ:CALC)…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 67.3% to $2.08 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. The company's, Q1 earnings…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's regular session. The market value of their outstanding shares is at $22.1 million. Icecure Medical…
benzinga.com FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial FDA raises no objections to CalciMedica revised Phase 2 KOURAGE trial, allowing Auxora dosing to resume for acute kidney injury.- benzinga.com Market-Moving News for June 24th FDX: -7% | FedEx shares are trading lower. The company reported Q4 financial results. LFS: 42% | LEIFRAS shares are trading higher after the company announced it will acquire SWIFT JAPAN. CALC: 60% |…
- benzinga.com CalciMedica Announces Private Placement Worth Up To ~$49M In Gross Proceeds The financing includes participation from new and existing investors, including members of CalciMedica's Board of Directors and management team. In the private placement, the Company will sell an…
- benzinga.com CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for
prnewswire.com CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral…
prnewswire.com CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com CalciMedica Q1 EPS $0.30 Beats $(0.28) Estimate CalciMedica (NASDAQ:CALC) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $(0.28) by 207.14 percent. This is a 183.33 percent increase over losses of…
prnewswire.com CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
prnewswire.com CalciMedica Reports 2025 Financial Results and Provides Clinical Updates Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ D esign of…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis CalciMedica, Inc. (NASDAQ: CALC) shares are down on Wednesday after the company announced the discontinuation of its Phase 2 KOURAGE clinical trial.
benzinga.com Nasdaq Gains 150 Points; Starbucks Shares Rise After Strong Sales 
prnewswire.com CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026…
zacks.com Airbus Clinches Contract to Supply 30 A320neo Aircraft to CALC EADSY lands a firm order for 30 A320neo aircraft from CALC, reinforcing strong global demand for its fuel-efficient single-aisle aircraft.
defenseworld.net CalciMedica (NASDAQ:CALC) Trading Down 2.1% – Time to Sell? CalciMedica Inc. (NASDAQ: CALC - Get Free Report) traded down 2.1% during trading on Tuesday. The company traded as low as $5.55 and last traded at $5.73. 44,801 shares were traded during mid-day…
prnewswire.com CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA on pivotal trial in acute…
prnewswire.com CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with…
prnewswire.com CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025 Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of…
prnewswire.com CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™ AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials LA JOLLA, Calif. , Oct. 14, 2025 /PRNewswire/…